Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Teva Reorganizes With Emphasis On Strengthening Generics

This article was originally published in The Pink Sheet Daily

Executive Summary

Former Actavis Pharma President Olafsson has been appointed president and CEO of the newly formed Global Generic Medicines Group, which will consolidate Teva’s regional generic businesses under one group.

You may also be interested in...

Mylan/Natco, Sandoz/Momenta Stew As Teva Cements Copaxone Loyalty

Teva’s multiple sclerosis drug Copaxone lost patent protection about three weeks ago. But according to some analysts an immediate generic substitution is still up in the air and the company has not lost the opportunity to capitalize in the interim by switching patients to a new three-injections-a-week formulation.

Teva CEO Suits Up For Acquisitions As A Springboard For Growth

In his first public comments to investors, CEO Erez Vigodman said he will consider large acquisitions to drive growth at Teva, while deepening cost cuts and refocusing on generics to maintain Teva’s leadership position.

Watson Begins Anew As Actavis, Focuses On Organic Growth

The traditionally generic-heavy company now has an expanded global presence and a growing branded business to go with its new name.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts